Pharma BD Deal Intelligence

Eli Lilly and Company / Dermira Inc.

2020 · Acquisition/Merger · $1.1B · Complete

Eli Lilly agreed to acquire Dermira for $18.75/share in cash, ~$1.1B total. The deal added lebrikizumab, a Phase 3 IL-13 monoclonal antibody for atopic dermatitis, plus marketed product Qbrexza for hyperhidrosis. Bolstered Lilly's immunology/dermatology pipeline alongside Taltz and Olumiant.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Jan 10, 2020
• Closed Feb 20, 2020
• Deal value $1.1B
• Deal type Acquisition/Merger
• Therapeutic area Moderate-to-severe atopic dermatitis (lebrikizumab Phase 3); primary axillary hyperhidrosis (Qbrexza approved)
• Indications Moderate-to-severe atopic dermatitis (lebrikizumab Phase 3); primary axillary hyperhidrosis (Qbrexza approved)
• Key assets Lebrikizumab (anti-IL-13 mAb); Qbrexza
• Mechanism IL-13 antagonist monoclonal antibody

← Browse all deals  ·  How we score deals